Caley Castelein Purchases Shares of Whitehawk Therapeutics
Insider Caley Castelein bought 38,040 shares of Whitehawk Therapeutics on June 12, 2026.
Key Points
- Caley Castelein bought 38,040 shares of Whitehawk Therapeutics on June 12, 2026.
- Whitehawk Therapeutics (NasdaqCM: WHWK) trades around $4.16, with a market cap of about $202.8 million.
- Analysts have set price targets up to $8.00, with a consensus 'buy' rating on the stock.
Caley Castelein, an insider at Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK), purchased 38,040 shares of the company on June 12, 2026. This transaction did not occur under a pre-planned trading agreement, and the shares were acquired at no disclosed purchase price.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, several insiders at Whitehawk Therapeutics, including Caley Castelein, Neil Desai, Emma Reeve, Richard Maroun, Baiteng Zhao, and Behzad Aghazadeh, each bought 38,040 shares. None of these transactions were part of a pre-arranged plan.
Other Institutional Activity in Whitehawk Therapeutics
Several institutional investors maintain significant holdings in Whitehawk Therapeutics. QVT Financial LP holds 4,615,709 shares valued at approximately $15.9 million, while OrbiMed Advisors LLC owns 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC has 3,700,000 shares valued at $12.8 million. Acuta Capital Partners, LLC and Avoro Capital Advisors LLC hold 3,410,402 and 2,849,402 shares, valued at $11.8 million and $9.8 million, respectively.
Whitehawk Therapeutics Stock Snapshot
Shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) are trading around $4.16. The company has a market cap of approximately $202.8 million and a forward P/E ratio that is not meaningful as the company isn't currently profitable. The stock has a 52-week low of $1.57 and a high of $5.50, with a 50-day moving average of $4.15 and a 200-day moving average of $2.98. The current ratio is notably high at 11.36, indicating strong liquidity.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics with a 'buy' rating and a price target of $8.00. Earlier, on December 22, 2025, Jones Trading also started coverage with a 'buy' rating and a $7.00 price target. The consensus among four analysts is a 'buy' rating, with an average target price of $6.50.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a biotechnology company focused on developing cancer treatments. Headquartered in Morristown, New Jersey, the company is led by CEO Dr. David J. Lennon. It specializes in oncology therapeutics and has a portfolio of next-generation antibody drug conjugates aimed at treating various cancers. Founded in 2007, Whitehawk employs 29 people.
Bottom Line
Insider purchases like those made by Caley Castelein can signal confidence in a company's prospects. Whitehawk Therapeutics, a clinical-stage biotech firm, is closely watched by investors for its innovative cancer therapies. It's important to note that insider transactions are reported after they occur, and the stock's performance may vary. Analysts are optimistic, with multiple 'buy' ratings and a price target range of $4.00 to $8.00.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.